Who is sponsoring NCT04045756?

NCT04045756 is sponsored by University of Rome Tor Vergata.

What drugs are being tested in NCT04045756?

Interventions in NCT04045756: Procedure/Surgery: Transperineal Focal Laser Ablation (TPLA).

What condition does NCT04045756 study?

NCT04045756 studies Prostate Cancer.

Is NCT04045756 still recruiting?

NCT04045756 is currently status unknown. Last updated 17 December 2019.

Last reviewed 2019-12-17 · How we verify

NCT04045756

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Focal Laser Ablation for the Treatment of Focal Low-Intermediate Risk Prostate Cancer

Status unknown NA Last updated 17 December 2019

What this trial tests

NA trial testing Procedure/Surgery: Transperineal Focal Laser Ablation (TPLA) in Prostate Cancer in 50 participants. Status unknown.

Timeline

2 August 2019

Primary endpoint
2 August 2020

2 August 2024

Quick facts

Lead sponsor	University of Rome Tor Vergata
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	50
Start date	2 August 2019
Primary completion	2 August 2020
Estimated completion	2 August 2024
Sites	1 location across Italy

Drugs / interventions tested

Procedure/Surgery: Transperineal Focal Laser Ablation (TPLA)

Conditions studied

Prostate Cancer — all drugs for Prostate Cancer →

Sponsor

University of Rome Tor Vergata

Who can join

Adults 46 to 86, male only, with Prostate Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Short-term Efficacy of Transperineal Laser Ablation (TPLA) with Image Fusion and Multi-parametric (mpMRI) Follow-up in Focal Low-intermediate Risk Prostate Cancer. It is an interventional pilot study. The clinical evaluation will be carried out at different times as follows: Time 0: recruitment and eligibility assessment (patient selection) Time 1: interview, signing of informed consent and enrollment Time 2: FLA treatment and control with multiparametric MRI of the post-procedural prostate. Time 3-4-5-6: follow up to 1 (T3), 6 (T4), 12 (T5) and 24 (T6) months from the procedure. The primary objective of the study is to evaluate the short-term (2 years) efficacy of FLA treatment of low-intermediate risk prostate cancer Secondary objective is to investigate multiparametric prostate MRI as a follow-up diagnostic investigation, evaluating possible glandular morphostructural changes and their correlation with clinical data.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Focal ablation therapy presents promising results for selectively localized prostate cancer patients.
Feng D, Li D, Xiao Y, Wu R, et al · · 2023 · cited 22× · PMID 37691892 · DOI 10.21147/j.issn.1000-9604.2023.04.08
Transperineal Laser Ablation (TPLA) Treatment of Focal Low-Intermediate Risk Prostate Cancer.
Manenti G, Perretta T, Nezzo M, Fraioli FR, et al · · 2024 · cited 10× · PMID 38611082 · DOI 10.3390/cancers16071404
TransPerineal Laser Ablation (TPLA) Treatment of Focal Low-Intermediate Risk Prostate Cancer
Manenti G, Perretta T, Nezzo M, Fraioli FR, et al · · 2024 · DOI 10.20944/preprints202402.1578.v1

Verify or expand the search:

Other recruiting trials for Prostate Cancer

Currently open trials in the same condition.

NCT06960798 — Characterizing the Genomic Landscape of Prostate Cancer in Native American Populations (NAT-Geno) · recruiting
NCT07237269 — Abi/Pred + ADT vs ADT in PSMA-Positive, Conventionally Node-Negative Prostate Cancer · Phase 2 · recruiting
NCT07234981 — PSMA-PET Guided De-escalation of Salvage Radiation Treatment in Recurrent Prostate Cancer · Phase 2 · recruiting
NCT07027124 — Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Ris · Phase 2 · recruiting
NCT07426094 — PRO-BOOST-N: Prostate-First Versus Combined Prostate and Nodal Dose Escalation in PSMA PET-Staged Node-Positive Prostate · Phase 2, PHASE3 · recruiting

Other University of Rome Tor Vergata trials

Trials by the same sponsor.

NCT07510698 — Same-Day Awake Mastectomy With Immediate Breast Reconstruction for Patients With Breast Cancer · NA · recruiting
NCT07313358 — 10119473 -VIROMARKERS HDV Biomarkers Study · not yet recruiting
NCT07286461 — VIROMARKERS GA n.101194735 - CMV and TTV Biomarkers Study Protocol · not yet recruiting
NCT07067749 — Treatment Expedition With MRI Processing and Optimization for Muscle Invasive Bladder Cancer · Phase 3 · recruiting
NCT06711744 — ISQ Differences Between Different Implants in Post-extraction Sockets · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04045756 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Rome Tor Vergata
Last refreshed: 17 December 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04045756.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing